To elucidate the relationship between EHD1 expression and EGFR-TKI resistance, we retrospectively evaluated specimens from a total of 24 lung cancer patients who had received EGFR-TKIs (erlotinib or gefitinib). The gene discussed is EGFR; the disease is lung carcinoma.